RxDoctor Payments Data

Elena Gabor, MD

Internal Medicine · Lake Mary, FLNPI 1417909821

Payments from drug & device makers

$3,228in general payments, 2019–2025

Across 146 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$515
  • Amgen$296
  • AstraZeneca$268
  • Abbott$260
  • Idorsia Pharmaceuticals US Inc$198
  • AbbVie$193
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,222100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,228 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$201,324
Medicare patients
320
Services billed
2,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$139,140
EliquisApixaban52$52,294
JardianceEmpagliflozin29$31,428
MounjaroTirzepatide22$25,328
RybelsusSemaglutide23$25,077
FarxigaDapagliflozin Propanediol19$24,424
Bydureon BciseExenatide Microspheres14$11,838
Soliqua 100-33Insulin Glargine/Lixisenatide11$10,118
Rosuvastatin Calcium631$9,855
LinzessLinaclotide15$9,041
VascepaIcosapent Ethyl15$7,883
NexletolBempedoic Acid14$7,875
SynthroidLevothyroxine Sodium71$7,262
SymbicortBudesonide/Formoterol Fumarate21$6,583
TradjentaLinagliptin11$6,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$515$164,217155 claims
PfizerEliquis$30$52,29452 claims
Boehringer IngelheimJardiance, Tradjenta$176$37,78640 claims
AstraZenecaFarxiga, Symbicort$268$31,00740 claims
Lilly USA, LLCMounjaro$94$25,32822 claims
AbbVieLinzess, Synthroid$193$16,30386 claims
Esperion Therapeutics, Inc.Nexletol$20$7,87514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →